ARTICLE | Clinical News
Antisoma down on extended trial
June 6, 2001 7:00 AM UTC
Antisoma (LSE:ASM; EASD:ASOM) was off 33.5p (18%) to 155p on LSE trading on Wednesday on news that it will extend the enrollment period in its Phase III SMART trial of pemtumomab (formerly Theragyn) i...